Seer (SEER) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$14.2M

Revenue (quarter)

$3.1M

Revenue growth (year over year)

−23.43%

Gross profit (trailing twelve months)

$6.8M

Gross margin

47.70%

Net income (trailing twelve months)

−$68.0M

Net income (quarter)

−$16.9M

Net income growth (year over year)

+13.00%

Net margin

−478.05%

Return on equity

−26.45%

EPS (trailing twelve months)

−$1.22

Book value per share

$4.08

P/E (trailing twelve months)

—

Price to book

0.51

Debt to assets

12.06%

Payout ratio

—

Dividend yield

—

Company profile

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

• Is Seer (SEER) profitable?

  No. Seer reported a net loss of $68.0M over the trailing twelve months.

• How much revenue does Seer (SEER) make?

  Seer generated $14.2M in revenue over the trailing twelve months, down 23.43% year over year.

• How do I buy stock in Seer (SEER)?

  SEER trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.